103例藥物性肝損傷的臨床分析
發(fā)布時(shí)間：2018-12-17 17:29
【摘要】：我們于臨床用藥的過程里,因藥物自身成分及/或經(jīng)其代謝產(chǎn)生的物質(zhì),或者因機(jī)體本身體質(zhì)的原因?qū)е碌母呙舾行曰蜉^低的耐受性而引起的肝功能異常或結(jié)構(gòu)改變稱為藥物性肝損傷(DILI)�，F(xiàn)如今,在我國由于大量藥物的頻繁使用,藥物性肝損傷(DILI)已經(jīng)成為一種重要的肝臟疾病,正日益加深的影響著人類的身心健康。然而,DILI無特異性的臨床癥狀及生化學(xué)指標(biāo)改變,診斷仍面臨困難,漏診及誤診率較高。針對(duì)該難題,中華醫(yī)學(xué)會(huì)肝病學(xué)分會(huì)于2015年發(fā)布我國第一個(gè)藥物性肝損傷診治指南,為藥物性肝損傷的診斷治療提供了依據(jù)。目的:依據(jù)藥物性肝損傷診斷指南,對(duì)山東省立醫(yī)院既往診斷為藥物性肝損傷病例行重新診斷,分析符合診斷標(biāo)準(zhǔn)者臨床特點(diǎn),明確可引起肝損害的具體藥物種類,引起肝損害的類型,對(duì)于以后臨床用藥、防止再次發(fā)生藥物不良事件提供依據(jù)。方法:搜索山東大學(xué)附屬山東省立醫(yī)院2014年1月1日至2016年12月31日肝病科診治的診斷為"藥物性肝損傷"、"藥物性肝炎"、"中毒性肝病"、"中毒性肝炎"病例128例,依據(jù)診斷指南對(duì)其再次診斷,排除掉RUCAM評(píng)分6分者25例,納入依據(jù)診斷標(biāo)準(zhǔn)評(píng)定為極可能或很可能為藥物性肝損傷者103例,進(jìn)行回顧性研究,就其一般情況(如年齡、性別、職業(yè))、臨床特點(diǎn)(包括體征、輔助檢查、臨床分型)、導(dǎo)致肝功能異常的藥物、治療方法、治療轉(zhuǎn)歸等情況進(jìn)行統(tǒng)計(jì)研究。結(jié)果:1.納入研究的病例中RUCAM評(píng)分8分所占比例最大(25.2%),其次為 7 分23.3%,9 分 22.3%,6分21.4%,10 分4.9%,12 分 1.9%,11 分 1.0%。2.藥物性肝損傷發(fā)病率逐年增高。3.發(fā)病平均年齡為46.75 ± 16.11。其中41-60歲所占比例最大(44.7%)。4.導(dǎo)致藥物性肝損傷的藥物中,中藥52例(43.7%),抗生素17例(14.3%),抗結(jié)核藥9例(7.6%),減肥及保健品4例(3.4%),抗甲狀腺藥3例(2.5%),非甾體抗炎藥3例(2.5%),保胃藥5例(4.2%)。5.臨床表現(xiàn)以惡心、納差,厭油,腹痛、腹瀉等消化道癥狀57例(43.8%),皮膚、鞏膜黃染及/或小便發(fā)黃45例(34.6%),乏力12例(9.2%),皮疹、皮膚瘙癢2例(1.5%),無癥狀14例(10.8%)。6.臨床分型:根據(jù)病程,急性藥物性肝損傷94例(91.2%),慢性藥物性肝損傷9例(8.8%);根據(jù)靶細(xì)胞類型,肝細(xì)胞型90例(87.4%),膽汁淤積型7例(6.8%),混合型6例(5.8%)。肝細(xì)胞型DILI ALT、AST水平較高,膽汁淤積性DILI GGT、ALP水平較高(P0.05)。7.臨床轉(zhuǎn)歸:治療好轉(zhuǎn)出院92例(89.3%),未見明顯好轉(zhuǎn)自動(dòng)出院9例(8.8%),死亡2例(1.9%)。結(jié)論:藥物性肝損傷(DILI)的發(fā)病率正一年高于一年,現(xiàn)已經(jīng)成為主要的肝功能及結(jié)構(gòu)損害原因之一。以女性及中老年人多見,臨床表現(xiàn)中以消化癥狀最多見�？梢砸鹚幬镄愿螕p傷的藥物為:中藥,抗生素,抗結(jié)核藥,減肥藥及保健品,抗甲狀腺藥,非甾體抗炎藥,保胃藥。急性DILI以及肝細(xì)胞型DILI最常見。患者大多預(yù)后良好。
[Abstract]:In the course of clinical use of drugs, the substances produced by the drug's own components and / or by its metabolism, Or liver dysfunction or structural change caused by high sensitivity or low tolerance due to the body's own physical condition is called drug-induced liver injury (DILI). Nowadays, due to the frequent use of a large number of drugs in China, drug-induced liver injury (DILI) has become an important liver disease, which is increasingly affecting the physical and mental health of human beings. However, DILI has no specific clinical symptoms and biochemical indicators, so the diagnosis is still difficult, and the rate of missed diagnosis and misdiagnosis is high. In order to solve this problem, the Chinese Society of Hepatology issued the first guidelines for the diagnosis and treatment of drug-induced liver injury in 2015, which provides a basis for the diagnosis and treatment of drug-induced liver injury. Objective: according to the guidelines for the diagnosis of drug-induced liver injury, we rediagnosed the patients with drug-induced liver injury in Shandong Provincial Hospital, analyzed the clinical characteristics of those who met the diagnostic criteria, and determined the specific drugs that could cause liver injury. The types of liver damage may provide evidence for clinical use of drugs to prevent the recurrence of adverse drug events. Methods: from January 1, 2014 to December 31, 2016, the Department of Hepatology of Shandong Provincial Hospital affiliated to Shandong University diagnosed as "drug-induced liver injury", "drug-induced hepatitis", "toxic liver disease", and "toxic hepatitis" in 128 cases. According to the diagnostic guidelines, 25 patients with RUCAM score 6 were excluded, and 103 patients who were assessed as most likely or most likely to be drug-induced liver injury according to the diagnostic criteria were included in a retrospective study on the general situation (such as age, sex, etc.) Clinical features (including signs, adjuvant examinations, clinical typing), drugs leading to abnormal liver function, treatment methods, outcome of treatment, etc. Results: 1. The RUCAM score of 8 was the largest (25.2%), followed by 7: 23.3and 9: 22.3. The incidence of drug-induced liver injury increased year by year. The mean age of onset was 46.75 鹵16.11. 41-60 years of age accounted for the largest proportion (44.7%). Among the drugs causing drug-induced liver injury, 52 cases (43.7%) were Chinese medicine, 17 cases (14.3%) were antibiotics, 9 cases (7.6%) were anti-tuberculosis drugs, 4 cases (3.4%) were slimming and health products. Antithyroid drugs were found in 3 cases (2.5%), non-steroidal anti-inflammatory drugs in 3 cases (2.5%), gastric preservatives in 5 cases (4.2%) and non-steroidal anti-inflammatory drugs in 5 cases (4.2%). The clinical manifestations were nausea, anorexia, oil, abdominal pain and diarrhea in 57 cases (43.8%), skin, yellowish sclera and / or urine yellowing in 45 cases (34.6%), fatigue in 12 cases (9.2%) and rash in 12 cases. There were 2 cases (1.5%) of pruritus and 14 cases (10.8%) of asymptomatic pruritus. Clinical classification: according to the course of disease, 94 cases (91.2%) were acute drug-induced liver injury, 9 cases (8.8%) were chronic drug-induced liver injury. According to target cell type, 90 cases (87.4%) were hepatocyte type, 7 cases (6.8%) were cholestasis type, 6 cases (5.8%) were mixed type. The level of hepatocyte DILI ALT,AST was higher, and the level of cholestatic DILI GGT,ALP was higher (P0.05). The clinical outcome: 92 cases (89. 3%) were cured, 9 cases (8. 8%) were left hospital without obvious improvement, 2 cases (1. 9%) died. Conclusion: the incidence of drug-induced liver injury (DILI) is more than one year and has become one of the main causes of liver function and structure damage. Most of them were female and middle aged, and digestive symptoms were most common in clinical manifestations. Drugs that can cause drug-induced liver injury are: traditional Chinese medicine, antibiotics, anti-tuberculosis drugs, diet and health products, anti-thyroid drugs, non-steroidal anti-inflammatory drugs, stomach protection drugs. Acute DILI and hepatocyte DILI are the most common. Most patients have a good prognosis.
【學(xué)位授予單位】：山東大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R575
[Abstract]:In the course of clinical use of drugs, the substances produced by the drug's own components and / or by its metabolism, Or liver dysfunction or structural change caused by high sensitivity or low tolerance due to the body's own physical condition is called drug-induced liver injury (DILI). Nowadays, due to the frequent use of a large number of drugs in China, drug-induced liver injury (DILI) has become an important liver disease, which is increasingly affecting the physical and mental health of human beings. However, DILI has no specific clinical symptoms and biochemical indicators, so the diagnosis is still difficult, and the rate of missed diagnosis and misdiagnosis is high. In order to solve this problem, the Chinese Society of Hepatology issued the first guidelines for the diagnosis and treatment of drug-induced liver injury in 2015, which provides a basis for the diagnosis and treatment of drug-induced liver injury. Objective: according to the guidelines for the diagnosis of drug-induced liver injury, we rediagnosed the patients with drug-induced liver injury in Shandong Provincial Hospital, analyzed the clinical characteristics of those who met the diagnostic criteria, and determined the specific drugs that could cause liver injury. The types of liver damage may provide evidence for clinical use of drugs to prevent the recurrence of adverse drug events. Methods: from January 1, 2014 to December 31, 2016, the Department of Hepatology of Shandong Provincial Hospital affiliated to Shandong University diagnosed as "drug-induced liver injury", "drug-induced hepatitis", "toxic liver disease", and "toxic hepatitis" in 128 cases. According to the diagnostic guidelines, 25 patients with RUCAM score 6 were excluded, and 103 patients who were assessed as most likely or most likely to be drug-induced liver injury according to the diagnostic criteria were included in a retrospective study on the general situation (such as age, sex, etc.) Clinical features (including signs, adjuvant examinations, clinical typing), drugs leading to abnormal liver function, treatment methods, outcome of treatment, etc. Results: 1. The RUCAM score of 8 was the largest (25.2%), followed by 7: 23.3and 9: 22.3. The incidence of drug-induced liver injury increased year by year. The mean age of onset was 46.75 鹵16.11. 41-60 years of age accounted for the largest proportion (44.7%). Among the drugs causing drug-induced liver injury, 52 cases (43.7%) were Chinese medicine, 17 cases (14.3%) were antibiotics, 9 cases (7.6%) were anti-tuberculosis drugs, 4 cases (3.4%) were slimming and health products. Antithyroid drugs were found in 3 cases (2.5%), non-steroidal anti-inflammatory drugs in 3 cases (2.5%), gastric preservatives in 5 cases (4.2%) and non-steroidal anti-inflammatory drugs in 5 cases (4.2%). The clinical manifestations were nausea, anorexia, oil, abdominal pain and diarrhea in 57 cases (43.8%), skin, yellowish sclera and / or urine yellowing in 45 cases (34.6%), fatigue in 12 cases (9.2%) and rash in 12 cases. There were 2 cases (1.5%) of pruritus and 14 cases (10.8%) of asymptomatic pruritus. Clinical classification: according to the course of disease, 94 cases (91.2%) were acute drug-induced liver injury, 9 cases (8.8%) were chronic drug-induced liver injury. According to target cell type, 90 cases (87.4%) were hepatocyte type, 7 cases (6.8%) were cholestasis type, 6 cases (5.8%) were mixed type. The level of hepatocyte DILI ALT,AST was higher, and the level of cholestatic DILI GGT,ALP was higher (P0.05). The clinical outcome: 92 cases (89. 3%) were cured, 9 cases (8. 8%) were left hospital without obvious improvement, 2 cases (1. 9%) died. Conclusion: the incidence of drug-induced liver injury (DILI) is more than one year and has become one of the main causes of liver function and structure damage. Most of them were female and middle aged, and digestive symptoms were most common in clinical manifestations. Drugs that can cause drug-induced liver injury are: traditional Chinese medicine, antibiotics, anti-tuberculosis drugs, diet and health products, anti-thyroid drugs, non-steroidal anti-inflammatory drugs, stomach protection drugs. Acute DILI and hepatocyte DILI are the most common. Most patients have a good prognosis.
【學(xué)位授予單位】：山東大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R575
【參考文獻(xiàn)】
相關(guān)期刊論文 前10條
1 黃海云;謝建云;黃永堅(jiān);林德美;吳川平;;新生兒常見疾病對(duì)骨堿性磷酸酶水平影響的探討及對(duì)佝僂病的防治[J];黑龍江醫(yī)學(xué);2016年12期
2 李俊;黃紹萍;陸基華;殷科珊;樊貞瑜;唐榮;徐烈;程計(jì)林;;藥物性肝損傷臨床特點(diǎn)及致病藥物回顧性分析[J];胃腸病學(xué)和肝病學(xué)雜志;2016年02期
3 Chia-Ying Yu;Liang-Che Chang;Li-Wei Chen;Tsung-Shih Lee;Rong-Nan Chien;Ming-Fang Hsieh;Kun-Chun Chiang;;Peliosis hepatis complicated by portal hypertension following renal transplantation[J];World Journal of Gastroenterology;2014年09期
4 許維國;韓濤;李瑩;劉華;趙曉華;趙秋瑩;;藥物性肝損傷臨床特點(diǎn)分析[J];武警后勤學(xué)院學(xué)報(bào)(醫(yī)學(xué)版);2014年02期
5 王雁;湯納平;馬t，
本文編號(hào)：2384560
本文鏈接：http://www.wukwdryxk.cn/yixuelunwen/xiaohjib/2384560.html
最近更新
教材專著
